Skip to main content
. Author manuscript; available in PMC: 2014 Jun 24.
Published in final edited form as: Vaccine. 2013 May 9;31(29):3025–3033. doi: 10.1016/j.vaccine.2013.04.050

Figure 3.

Figure 3

a-d. ELISA: 3.a-b. ELISA conducted at Bavarian Nordic using BN MVA as the assay antigen, positive titer ≥50. Time points represent the number of days after the first vaccination for all three groups (3.a.) and after last vaccination for all three groups, i.e. after the single vaccination in Group:0, and after the second vaccination for the other two groups (Group:0+7 and Group:0+28) (3.b.) vaccinations. Placebo recipient data is not shown. 3.c-d. ELISA Antibody conducted at Saint Louis University using ATCC MVA (VR-1508) as the assay antigen, positive titer > 50. Time points represent the number of days after the first vaccination for all three groups (3.c.) and after last vaccination for all three groups, i.e. after the single vaccination in Group:0, and after the second vaccination for the other two groups (Group:0+7 and Group:0+28) (3.d.). Placebo recipient data is not shown.